Task Force 5: Systemic hypertension

Task Force 5: systemic hypertension.

Task force 5: Expert testimony and opinions.

Members of the ACCF or the AHA have a variety of roles aside from their professional relationships with these organizations. Delineation of these varying roles may not always be entirely clear. A member’s particular expertise in research or as a care provider naturally provides the impetus for his or her official contributions to the organization’s programs, written position statements, and gui...

COCATS 4 Task Force 5: Training in Echocardiography.

Rev Date: 12/19/2014 Page 1 of 24 Q:\C&T\COCATS4\PC\TF5-Echo NOTE: This preliminary document contains proprietary information. It is posted for public comment and subject to change. It should not be disseminated except for review and comment for this public comment process. The final document will be revised and approved by the ACC Board of Trustees and endorsing organizations and published in ...

5-HT in systemic hypertension: foe, friend or fantasy?

Since its discovery by Erspamer in the 1930s and identification by Page in the 1950s, 5-HT (5-hydroxytryptamine; serotonin) has been an elusive candidate as a substance that plays a role in the disease of high blood pressure, also known as hypertension. In both animal and human hypertension, arterial contraction to 5-HT is profoundly enhanced. Additionally, 5-HT is a vascular smooth muscle cell...

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.

Reappraisal of European guid elines on hypertension management: a European Society of Hypertension Task Force document Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjel...